
    
      This trial is a single-arm, non-randomized and single-center clinical study of targeted
      therapy combined immunotherapy in patients with hepatobiliary malignant tumors.

      It is estimated that 50 patients who met the study criteria will be enrolled in PUMCH and
      treated with lenvatinib and pembrolizumab. The investigators will follow up and collect
      subjects' data each month to evaluate the efficacy and safety of treatment, including overall
      survival and time to progression. Multi-omics data analysis will be used to find potential
      biomarkers of treatment response.
    
  